CASE COMMENT: UNILATERAL PRACTICES - ABUSE OF DOMINANT POSITION - RESTRICTION OF SUPPLY - PHARMACEUTICAL PRODUCTS

Pharmaceutical products: The Advocate General Jacobs suggests a restriction of supply leading to a limited parallel trade is not necessarily significant of an abuse of dominant position (Syfait/Glaxosmithkline)

L'avocat général Jacobs vient de rendre ses conclusions dans l'affaire opposant seize grossistes en produits pharmaceutiques à la société pharmaceutique Glaxosmithkline, en position dominante sur le marché des médicaments anti-épileptiques avec le Lamictal. La Commission hellénique de la concurrence (Epitropi Antagonisomu) a introduit, sur le fondement de l'article 234 du traité, une question

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

  • L’actu-concurrence

Quotation

Alain Ronzano, Pharmaceutical products: The Advocate General Jacobs suggests a restriction of supply leading to a limited parallel trade is not necessarily significant of an abuse of dominant position (Syfait/Glaxosmithkline), 28 October 2004, Concurrences Review N° 1-2005, Art. N° 57629, www.concurrences.com

Visites 26

All reviews